Haleon plc reported routine share plan transactions by two senior executives under its Share Reward Plan. On 10 February 2026, General Counsel Adrian Morris acquired 31 ordinary shares at £3.956 as Partnership Shares and received 31 Matching Shares at no cost, for an aggregated volume of 62 shares. On the same date, President, Europe Jonathan Workman acquired 32 Partnership Shares at £3.956 and received 32 Matching Shares at no cost, an aggregated 64 shares. All transactions involved ordinary shares of £0.01 each, traded on the London Stock Exchange.
Wellington Management Group LLP and related entities report their ownership of Haleon plc common stock on an amended Schedule 13G. As of 12/31/2025, they beneficially own 443,046,686 shares, representing 4.97% of the class, with shared voting and dispositive power through investment adviser clients.
The securities are held in the ordinary course of business by Wellington-managed clients and are not held for the purpose of changing or influencing control of Haleon. No individual client is reported to hold more than five percent of the class.
Haleon plc has updated its share capital and voting rights information. As at 31 January 2026, the company has issued 8,952,353,648 ordinary shares of £0.01 each, of which 45,557,120 shares are held in treasury. This leaves 8,906,796,528 ordinary shares with voting rights.
Shareholders and others with notification obligations under the FCA's Disclosure Guidance and Transparency Rules are instructed to use the voting-rights figure as the denominator when assessing whether they must report their holdings or changes in their interest in Haleon.
Haleon plc filed a report noting an additional external role for its Chief Financial Officer. Dawn Allen, Haleon’s CFO, has been appointed Chair of the Audit & Risk Committee of ITV plc, effective 5 March 2026. She has already been serving as a Non-Executive Director of ITV and a member of its Audit & Risk Committee since 2 October 2023.
The update is described as a director declaration made in line with Listing Rule 6.4.9R(2). Haleon also reiterates that it is a global consumer health company with a portfolio of well-known brands including Advil, Centrum, Panadol, Sensodyne, Theraflu and Voltaren.
Haleon plc outlined an evolution of its operating model to support its “Win as One” strategy, aiming to drive growth, productivity and culture, with changes expected to be implemented by mid-2026. The company has created a new Chief Growth Officer role that will oversee Category, Marketing and Strategy functions, plus a new global Commercial Excellence team, and will lead the growth and innovation agenda together with R&D, Supply Chain and new Operating Units.
Haleon is also reorganising into six Operating Units, splitting the current EMEA & LatAm region into Latin America, Middle East and Africa, and Europe, and establishing India Subcontinent as its own unit separate from Asia Pacific, while North America remains unchanged. In addition, a new Chief Transformation Officer will coordinate transformation across business processes, the operating model and technology. The CGO, CTO and each Operating Unit President will join the Executive Committee and report to CEO Brian McNamara. Further detail is expected with the Preliminary Full Year Results scheduled for 25 February 2026.
Haleon plc reported routine share transactions by two senior executives under its Share Reward Plan. The company disclosed that on 5 January 2026, General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers, both classified as persons discharging managerial responsibilities (PDMRs), acquired ordinary shares in Haleon.
Each PDMR acquired 34 Partnership Shares in Haleon at a price of £3.71 per share and received an award of 34 Matching Shares at £0, giving an aggregated volume of 68 ordinary shares per person. The transactions took place on the London Stock Exchange and were reported in line with UK Market Abuse Regulation requirements.
Haleon plc announced changes to its board and committees. Alan Stewart will become Senior Independent Director when Vindi Banga is appointed Chair with effect from 1 January 2026. Stewart joined the board in September 2024 as a Non-Executive Director and Chair of the Audit & Risk Committee, and he will retain that position while also remaining on the Remuneration, Nominations & Governance and Environmental & Social Sustainability Committees.
In line with the UK Corporate Governance Code 2024, Vindi Banga will step down from the Audit & Risk Committee and the Remuneration Committee on 31 December 2025 and will become Chair of the Nominations & Governance Committee from 1 January 2026. Haleon confirmed that Banga’s remuneration as Chair will be £757,103 per annum, with further details to be included in the Company’s 2025 Annual Report & Accounts.
Haleon plc reported routine share transactions by two senior executives under its Share Reward Plan. On 9 December 2025, General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers each acquired 35 partnership shares in Haleon at a price of £3.57201 per ordinary share and received 35 matching shares at no cost. These ordinary shares have a nominal value of £0.01 each and are listed on the London Stock Exchange. The disclosure is made in line with UK Market Abuse Regulation requirements for transactions by persons discharging managerial responsibilities.
Haleon plc reported its share capital and voting rights as of 30 November 2025. The company has issued a total of 8,952,353,648 ordinary shares of £0.01 each, of which 45,882,158 are held as treasury shares. This leaves 8,906,471,490 ordinary shares with voting rights.
The company states that this voting-rights figure should be used by shareholders and others with notification obligations as the denominator when calculating whether they must disclose their interest in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc reported PDMR share transactions under its Share Reward Plan. On 11 November 2025, Adrian Morris (General Counsel) and Tamara Rogers (Chief Marketing Officer) each acquired 33 ordinary shares at £3.718992 and received 33 matching shares at £Nil on the London Stock Exchange.
These notifications were made in accordance with the UK Market Abuse Regulation and reflect routine participation in the company’s employee share plan.